Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00no prior Q3 2023 on file Net Income-$62.79M-$62.79MN/M vs Q3 2023 EPS Diluted-$0.81-$0.81N/M vs Q3 2023 Operating Income-$73,676,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$50,255,000N/M ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end